NSE: APOLLOHOSP · BSE: 508869 · ISIN INE437A01024
Apollo Hospitals Enterprise Limited stock analysis
Apollo Hospitals Enterprise Limited ranks #1429 in the TickerSutra evidence-ranked universe with a score of 53/100 and 95% data confidence. The latest captured fundamentals show ROCE of 17.4%, quarterly sales growth of 20.6% and quarterly profit growth of 34.2%.Monitor only
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- CWIP indicates an active capacity pipeline
Risks and constraints
- Debt/equity is above 0.5×
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹14,663cr | ₹2,189cr | ₹1,108cr | 15.0% |
| 2023 | ₹16,612cr | ₹2,065cr | ₹844cr | 12.0% |
| 2024 | ₹19,059cr | ₹2,394cr | ₹935cr | 13.0% |
| 2025 | ₹21,794cr | ₹3,033cr | ₹1,505cr | 14.0% |
| 2026 | ₹25,228cr | ₹3,779cr | ₹2,003cr | 15.0% |
| TTM | ₹26,430cr | ₹4,010cr | ₹2,172cr | 15.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
MANAGEMENT COMMENTARY
Signals from filed documents
Rising Investments in the Indian Healthcare space: The Indian healthcare sector continues to attract strong investor inter est, supported by structural demand growth, cost competitiveness and an evolving policy environment. Continued investments are supporting capacity expansion, technology adoption and service diversi/f_ication across the healthcare ecosystem. The Indian hospital sector in FY27 is expected to witnes
The Company remains focused on enhancing realizations through a higher share of complex procedures and an improving payer mix. These factors, along with continued cost optimization and operating leverage, are expected to support margin expansion and sustained improvement in return ratios over the medium term. The Diagnostics and Retail Health business will continue to play a complementary role in strengthening the ov
The Company remains focused on enhancing realizations through a higher share of complex procedures and an improving payer mix. These factors, along with continued cost optimization and operating leverage, are expected to support margin expansion and sustained improvement in return ratios over the medium term. The Diagnostics and Retail Health business will continue to play a complementary role in strengthening the ov
The facility is evolving into a Centre of Excellence in exosome biology, liquid biopsy and personalised medicine, enabling end-to-end translational research across: Advancing Clinical Research through Knowledge Sharing Apollo Research and Innovations (ARI) continued to str engthen Apollo Hospitals’ clinical research ecosystem by enhancing research quality, regulatory compliance and investigator capabilities. Through
Instead, the remuneration framework maintains a strong performance orientation through disciplined goal- setting, rigorous assessment of outcomes and the use of performance-based cash bonuses. For below-Board management, Apollo Hospitals operates the Apollo Hospitals Enterprise Limited Employee Stock Option Plan, approved by shareholders at the 2024 Annual General Meeting. The plan is intended to attract, reward and
Robust internal controls support asset protection, /f_inancial reporting integrity and compliance across the organization 4.2. Threats 01 02 03 04 Management Discussion & Analysis (Contd.) Regulatory Environment Availability of Skilled Healthcare Professionals Cost Pressures & Capital Intensity Competitive Landscape • Pricing controls and r eimbursement restrictions • Evolving compliance requirements • Shortage of sk
The trade receivables comprise mainly of receivables from insurance companies, corporate customers and government undertakings (both domestic and international). Customer Concentration No single customer represents 10% or more of the Company’s total revenue during the year ended March 31, 2026 and March 31, 2025. Therefore the customer concentration risk is limited due to the large and unrelated customer base.
Press Releases made by the Company from time to time are also posted on the Company’s website. Presentations made to the institutional investors and analysts after the declaration of the quarterly, half-yearly and annual results are also posted on the Company’s website. The Company also informs by way of intimation to the Stock Exchanges all price sensitive information or such other matters which in its opinion are m
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…